Direct activation of AMP-activated protein kinase (AMPK) using compound 991 — a small molecule that binds AMPK allosterically, bypassing the indirect metabolic effects of drugs like metformin — extended lifespan in three evolutionarily distinct organisms: the fruit fly Drosophila melanogaster, the nematode Caenorhabditis elegans, and the fission yeast Schizosaccharomyces pombe. In mice, 991 treatment induced proteomic changes consistent with a pro-longevity profile, suggesting mammalian translatability.
This finding matters because AMPK is one of the most heavily studied longevity nodes in biology, yet the field has long struggled to disentangle AMPK-specific effects from the broader metabolic noise created by indirect activators like metformin, which also inhibits mitochondrial Complex I and affects gut microbiota. Compound 991 provides a cleaner pharmacological tool to attribute lifespan extension specifically to AMPK activation — a genuinely important methodological advance. Cross-species replication across three divergent organisms substantially strengthens the claim that this is a conserved longevity mechanism rather than a species quirk.
Critical caveats apply: this is entirely animal and yeast evidence. No human trials exist. Mouse data here is proteomic only — not survival data — which is a notable gap. Whether compound 991 or analogues are safe or bioavailable in humans remains unknown. Still, as proof-of-principle that targeted AMPK activation alone is sufficient for lifespan extension, this is a meaningful incremental advance in the search for druggable longevity targets.